BLOOD CANCER
Epigenetic Therapy Cancer Treatment
Epigenetic Therapy: A Breakthrough in Blood Cancer Treatment
Traditional cytotoxic drugs often stimulate cancer stem cells making tumor recurrence nearly inevitable. In contrast, epigenetic therapies offer a durable, targeted approach by exploiting underlying cellular alterations to fundamentally change patient outcomes.
First FDA Approved Agent
Decitabine (a derivative of Azacitidine) revolutionized hematologic care by demonstrating remarkable success in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
Proven Survival Benefits
The landmark AZA001 clinical study established 5-aza as a preferred, high impact treatment for high risk MDS patients, significantly reducing the risk of leukemic transformation
Precision Targeting: EZH2 Inhibitors
Many hematopoietic tumors carry genetic alterations that increase lysine 27 methylation, leading to an adverse prognosis. EZH2 inhibitors directly target these specific mutations.
While EZH2 commonly functions as an oncogene, it can also act as a tumor suppressor in myeloid neoplasia, making precise inhibition essential.
The Clinical Challenge of Non-Selectivity
While traditional epigenetic drugs like decitabine show incredible promise, they can become refractory because their DNA-level mechanisms are unselctive.
For example, while decitabine successfully demethylates oncosuppressor genes, it can simultaneously activate oncopromters (like S100B), highlighting the strict need for more sophisticated, selective therapies.
The Promise of MTET: Next Generation Epigenetic Treatment
To overcome the limitations of traditional, unselective drugs, Cancer Research and Life Foundation is pioneering clinical trials for a novel Modified Multi Molecular Targeted Epigenetic Therapy (MTET) protocol.
MTET represents a monumental leap forward in three distinct ways
01
True Selectivity
Designed to precisely target and restore oncosuppressor genes without accidentally unleashing harmful cancer promoter genes
02
Dual Action Mechanism
Successfully combines critical histone epigenetic alterations with DNA epigenetic alterations simultaneously, a long standing hurdle in oncology research.
03
Dynamic Potency
Offers flexible potency that adapts to the shifting, complex epigenetic platform of cancer aberrancies, including comprehensive targeting of the critical EZH2 gene.